Abstract
The antitumor activity and side effects of the drug combinations prospidin + doxorubicin and prospidin hydrogel + doxorubicin were studied in rats with transplanted Zajdel ascites hepatoma. Test animals were divided into one control group and five test groups depending on the therapy protocol. Control animals were not treated. Test groups received (i) an aqueous solution of prospidin; (ii) prospidin hydrogel; (iii) doxorubicin; (iv) prospidin + doxorubicin; and (v) prospidin hydrogel + doxorubicin. The maximum tolerated doses (MTDs) of the drugs were used in monotherapy; half the MTD, in combination chemotherapy. The antitumor activity was evaluated in terms of lethality, lethality from tumor progression, total cure rate, average life expectancy, and prolonged life expectancy. Side and toxic effects were evaluated using data on the blood cell composition and biochemical parameters. It was established that the antitumor activity of combined aqueous prospidin and doxorubicin did not exceed the activity of doxorubicin monotherapy. Side effects of this combination had the same character as those of doxorubicin and were represented by leuko- and thrombocytopenia and nephropathy. The antitumor effect of combined prospidin hydrogel + doxorubicin with respect to lethality was significantly more pronounced than the effect of each individual component. This combination had a statistically significantly lower toxicity than that of the most toxic component.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
